Male sex steroids (androgens) sculpture the human embryo resulting in development of the male internal and external genitalia. At puberty, a surge of androgens leads to the initiation of spermatogenesis and growth of accessory sex organs, including the prostate gland. Sperm production is highly dependent on androgens (Zirkin et al., 1989) and it has long been suspected that suboptimal androgen action is one of the aetiological factors in idiopathic male infertility (Aiman and Griffin, 1982) . Since most infertile males have normal amounts of serum androgen (Niechlag et al., 1979) , it is possible that defective spermatogenesis could be the result of impaired androgen responsiveness. The cloning of the androgen receptor gene (Lubahn et al., 1988) and elucidation of its signal transduction pathway (Jenster et al., 1991) have provided new methods for investigating the role of androgen receptor mutations in male infertility. All androgens transmit their multifaceted effects through a single receptor: the androgen receptor (AR). The AR, a member of the steroid receptor superfamily, is a nuclear transcription factor that, when activated by androgens, switches on androgen-regulated genes that lead to spermatogenesis and prostate gland development (for review see Quigley et al., 1995) . Mutations of the androgen receptor are tolerated because the receptor is not essential for life and, in males, mutations of the X-linked receptor are expressed, providing a natural 'knockout system' for studying the phenotypic effects of the gene. The AR gene encodes a receptor protein of apparent molecular mass 110-114 kDa including 910-919 amino acids. The fulllength AR, like other steroid receptors, is a single polypeptide composed of three main functional domains: the transactivation domain, the DNA-binding domain and the ligandbinding domain (Fig. 1) .
Since the definition of the exon-intron boundaries of the androgen receptor gene, over 300 androgen receptor mutations (Gottlieb et al., 1998) have been reported in the ligand-binding and DNA-binding domains, making it the most naturally mutated transcription factor known. Most mutations are identified because they disrupt receptor function totally, causing complete androgen insensitivity syndrome, wherein a healthy 46XY individual is born with female external genitalia (Lim et al., 1997) . Mutations that do not completely disrupt androgen receptor function cause the partial syndrome, in which various degrees of ambiguous genitalia, including partial labioscrotal fusion, hypospadias, bifid scrotum and gynaecomastia, occur (Yong et al., 1998a) . Mutations of the ligand-binding and DNAbinding domains that cause complete and partial androgen insensitivity syndromes have been reviewed comprehensively by Quigley et al. (1995) and will not be discussed here.
Relatively few mutations have been reported in the transactivation domain because its large size (it comprises half of the receptor) and high GC content make genetic screening difficult. The transactivation domain is essential for receptor function and its deletion leads to a non-functional protein in vitro (Jenster et al., 1991) . This domain is of particular interest because of its causative relationship to a fatal neuromuscular disease, spinal bulbar muscular atrophy (Kennedy's syndrome). This review will focus on the novel hypothesis that Male sex steroids (androgens) are important for maintaining sperm production and growth of the accessory sex organ, the prostate gland. This article examines the role of the androgen receptor (AR) in the control of spermatogenesis and focusses on the N-terminal transactivation domain of the receptor, a poorly studied region that is essential for receptor function. This domain is of great interest because of its causative relationship to a fatal neuromuscular disease, spinal bulbar muscular atrophy (Kennedy's syndrome). Genetic screening of the transactivation domain of the AR gene of 153 patients presenting solely with defective spermatogenesis and male infertility, and of over 72 healthy fertile controls was performed. Up to 20% of infertile males have reduced androgenicity caused by an increase in length of a polymorphic trinucleotide (CAG) repeat segment, encoding a polyglutamine tract, of the androgen receptor. The increased risk of male infertility associated with long CAG lengths is associated with reduced risk of prostate cancer. Conversely, short polyglutamine tracts are associated with increased risk of prostate cancer but a reduced risk of male infertility. Thus depressed spermatogenesis and prostate cancer represent opposite ends of the spectrum of androgen receptor transactivation function. Improved understanding of androgen receptor action in these two important public health concerns could lead to rational and effective prevention and therapy.
polymorphisms and mutations affecting the transactivation domain of the androgen receptor can cause subtle disruption of receptor function and impairment of human spermatogenesis without any associated defect in secondary sexual characteristics. The transactivation domain of the androgen receptor gene of 191 patients with male infertility due to defective spermatogenesis and 101 healthy fertile controls was screened for mutations. Genetic screening has revealed triplet repeat polymorphisms that increase the risk of male infertility, and a point mutation in the transactivation domain that causes subtle impairment of receptor activity.
Triplet repeat polymorphisms in the transactivation domain
Exon 1 of the androgen receptor gene, which encodes the transactivation domain, contains several regions consisting of repeats of three nucleotides ( Fig. 1) . Two of these segments are polymorphic, varying in size among normal individuals. The most interesting of these is the segment consisting of multiple copies of the three nucleotides (CAG) that code for glutamine. The CAG repeat segment contains an average of 21 ± 2 repeats with a range of 14-31 in the normal fertile male population (Tut et al., 1997) . Further downstream is an invariate stretch of eight (CCG)s, coding for eight proline residues. Closer to the DNAbinding domain is the other polymorphic region consisting of multiple repeats of codon GGC, which codes for the amino acid, glycine. This polyglycine tract consists of 24 GGC repeats and also differs among normal individuals. The crystal structure of the N-terminal domain is not known and this region is the most variable among the steroid receptors. The N-terminal transactivation domain has been the source of great interest in recent years because of the discovery that expansion of the CAG repeat in the androgen receptor leads to spinal bulbar muscular atrophy (SBMA), a fatal neuromuscular disease (La Spada et al., 1991) . Trinucleotide repeat expansions are now implicated in many neuromuscular diseases (Mitas, 1997), including fragile X syndrome, Huntington's disease, spinocerebellar ataxia type 1, dentatorubral-pallidoluysian atrophy, Machado-Joseph's disease and Friedrich's ataxia. In all these diseases, the polymorphic trinucleotide repeats were expanded well beyond the range that occurred in normal unaffected persons. Thus, in the androgen receptor, SBMA patients have ≥ 40 CAG repeats compared with ≤ 35 in the normal population. The aetiology of trinucleotide expansions and the molecular mechanism of pathogenesis of neurological disease in SBMA is not known but is a subject of intense research.
Patients with SBMA also have evidence of reduced androgen receptor function in the form of gynaecomastia, oligospermia (reduced sperm production) or azoospermia (no sperm production), testicular atrophy and reduced fertility. Investigators have also found an inverse relationship between polyglutamine length and androgen receptor function by expressing androgen receptor constructs of different CAG lengths in cell lines and measuring the androgen receptor function by using reporter genes containing androgen response elements. When androgen receptors with deleted polyglutamine tracts were assayed for their abilities to activate transcription of several different androgen receptor-responsive reporter genes, it was found that elimination of the tract in both human and rat androgen receptors resulted in increased transcriptional activation activity (Chamberlain et al., 1994) . Progressive expansion of the CAG repeat in the human androgen receptor caused a linear decrease in transactivation function but did not completely eliminate androgen receptor activity. A polyglutamine tract of normal size represses androgen receptor transactivation function and polyglutamine expansion increases that effect. The relationship between polyglutamine tract and androgen receptor transactivation was inverse and linear from 0 to 50 glutamines (KazemiEsfarjani et al., 1995) .
Short CAG repeats associated with increased risk for prostate cancer
Besides the pathological expansions of polyglutamine lengths found in SBMA, alleles of different sizes within the normal polymorphic range were found to be associated with the androgen-dependent tumour, prostate cancer. (Hardy et al., 1996) . In another large case control study of 587 cases of prostate cancer and 588 controls, it was found that men with ≤ 18 CAG repeats have a 1.5-fold higher risk of prostate cancer than men with ≥ 26 repeats (Giovanucci et al., 1997) . The shorter repeat sequence was also associated with extraprostatic extension and distant metastasis. In an analysis of 301 cases, it was calculated that there was a 3% decreased risk in prostate cancer for each additional CAG repeat (Stanford et al., 1997) . Collectively, these data suggest that short CAG repeats have led to increased androgen receptor androgenicity and abnormally high prostatic growth with a resultant earlier age of onset, increased tumour grade and increased risk of extra-prostatic extension in prostate cancer. 
CAG repeats and defective spermatogenesis
If short CAG lengths can lead to disease in androgendependent tissues, at the other end of the spectrum, long CAG repeats might in a similar fashion cause reduced androgen receptor androgenicity and disease. Such a disease must be one that is extremely sensitive to reduction of androgen receptor function. In this light we decided to investigate spermatogenesis and CAG length. Spermatogenesis is very dependent on large amounts of androgens. Testicular androgen concentrations are about 50-100 times higher than they are in peripheral blood and lowering of androgen concentrations causes severe disruption of sperm production (McLachlan et al., 1996) . The lengths of the predicted polyglutamine and polyglycine repeats in 153 patients with defective sperm production were compared with those of 72 normal controls of proven fertility by measuring the size of their CAG and GGC repeat segments (Tut et al., 1997) . The polyglycine tract was less polymorphic and consisted of seven alleles. There were no significant differences in the size of the polyglycine tracts between patients and controls. In contrast, the distribution of alleles encoding the polyglutamine tract suggested that patients with reduced sperm counts differed significantly, with respect to the prevalence of glutamine number beyond 27, when compared with normal fertile controls. Patients with ≥ 28 glutamines in their androgen receptor had more than a fourfold increased risk of reduced spermatogenesis. There was also a trend whereby the more severe the spermatogenic defect, the higher the proportion of patients with the longer polyglutamine alleles. The risk of reduced spermatogenesis was halved with short repeat lengths ≤ 23 Gln. For glutamine repeats ≤ 21, the odds ratio was 0.44 suggesting that the shorter the length the lower the chance of defective spermatogenesis. The data indicate an inverse relationship between the length of the polyglutamine tract in the androgen receptor and the risk of reduced spermatogenesis (Fig. 2) . Receptors with polyglutamine lengths of ≤ 23, the same size that was found to give an excessive risk of prostate cancer (Irvine et al., 1994) , were associated with a reduced risk of male infertility, suggesting that the greater androgenicity associated with the shorter glutamine repeats could boost germ cell replication but with the long-term risk of overstimulating the growth of prostatic tissue.
This study was extended to include over 300 patients, and comparing CAG lengths, in cases with male infertility, prostate cancer and healthy fertile controls, using an automated Genescan technique with internal size markers to minimize errors in assignation of repeat size (Yong et al., 1998b) . It was found that CAG lengths fall into the following pattern: male infertility > normal controls > prostate cancer. The increased risk of male infertility associated with long CAG lengths was associated with a reduced risk of prostate cancer. Conversely, short polyglutamine tracts are associated with increased risk of prostate cancer but a reduced risk of male infertility. Thus, it appears that extremes of variation in androgen receptor polyglutamine length, associated with high or low receptor activity, in the normal population can lead to disease.
Gene transfer experiments, in which androgen receptor constructs with 15, 20 and 31 glutamine repeats, and a luciferase reporter gene with an androgen-response-element promoter, were co-expressed in vitro, confirmed an inverse relationship between number of glutamines and transregulatory activity (Tut et al., 1997) . The data indicate a direct relationship between the length of the polyglutamine tract and the risk of defective spermatogenesis that is attributable to the decreased functional competence of androgen receptor with longer glutamine tracts. Collectively, the evidence supports the hypothesis that the glutamine repeat fine-tunes the balance between excess and deficient receptor function. The highly polymorphic nature of the glutamine repeat would imply a subtle gradation of receptor function among individuals, possibly allowing alleles with evolutionary advantages to be rapidly selected and transmitted to future generations. This function of the androgen receptor polyglutamine length could be essential in view of the changing amounts of steroid substances in the environment and the demands of reproduction versus the requirements of other tissues affected by androgen.
It should be noted that the maximum polyglutamine length in these studies was 31, which is fewer than the 40 or more found in SBMA patients. None of the patients with expanded CAG repeat segments exhibited any sign of neuromuscular disease. Moderate expansion of the polyglutamine tract (28-31 Gln) exerts a modulatory effect on usual androgen receptor function, whereas expansion beyond a threshold (≥ 40 Gln) is likely to trigger a separate process that is neurotoxic (Fig. 2) . It is estimated that between 10 and 20% of patients with male infertility could have reduced androgen receptor function as a result of long polyglutamine tracts.
Mutational hot spot in the transactivation domain
Besides the CAG repeat, genetic screening of the transactivation domain in patients with male infertility revealed three different single strand conformation polymorphisms and sequencing of the mutant fragments revealed three G→A transitions in codons 210, 211 and 214 (Wang et al., 1998b) . The first two mutations were polymorphisms and the transition in codon 211 was related to ethnic origin, occurring in 10-15% of Indian or Middle-Eastern subjects, but not in ethnic Chinese who comprise the majority of the subjects. These two polymorphisms could therefore be useful in tracking racial origins.
The third mutation resulted in a non-conservative glycine to arginine substitution at codon 214 (G214R) and was associated with about 20% lower transactivation capacity than the wild type. The G214R mutation was found in a patient with male infertility as well as in a fertile control. Thus, although a possible pathogenic mutation was uncovered, mutations of the nonpolymorphic portions of the transactivation domain do not appear to have a major role in the aetiology of idiopathic male infertility.
Conclusion
These naturally occurring mutations and polymorphisms indicate that the transactivation domain has an important function in modifying androgen receptor activity. A full understanding of the function of this domain would lead to better understanding of the aetiology of male infertility and prostate cancer. A challenge for the future is to determine the mechanisms by which this is achieved and to devise rational therapeutic measures for these distressing conditions.
